. 2017 Sep 19;5(1):77.

doi: 10.1186/s40425-017-0278-6.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

Affiliations

¹ Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA.
² The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA.
³ Knight Cancer Institute at Oregon Health & Science University, Portland, OR, 97239, USA.
⁴ Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, 02139, USA.
⁵ University of California San Francisco, San Francisco, CA, 94143, USA.
⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21287, USA.
⁷ Oregon Health & Science University, Portland, OR, 97239, USA.
⁸ Harvard Medical School, Boston, MA, 02115, USA.
⁹ Yale School of Medicine, New Haven, CT, 06520, USA.
¹⁰ Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
¹¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
¹² Yale School of Medicine, 15 York Street, St LMP 5031, New Haven, CT, 06510, USA. marcus.bosenberg@yale.edu.

PMID: 28923102
PMCID: PMC5604351
DOI: 10.1186/s40425-017-0278-6

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

Andrew Zloza et al. J Immunother Cancer. 2017.

. 2017 Sep 19;5(1):77.

doi: 10.1186/s40425-017-0278-6.

Authors

Affiliations

¹ Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA.
² The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA.
³ Knight Cancer Institute at Oregon Health & Science University, Portland, OR, 97239, USA.
⁴ Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, 02139, USA.
⁵ University of California San Francisco, San Francisco, CA, 94143, USA.
⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21287, USA.
⁷ Oregon Health & Science University, Portland, OR, 97239, USA.
⁸ Harvard Medical School, Boston, MA, 02115, USA.
⁹ Yale School of Medicine, New Haven, CT, 06520, USA.
¹⁰ Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
¹¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
¹² Yale School of Medicine, 15 York Street, St LMP 5031, New Haven, CT, 06510, USA. marcus.bosenberg@yale.edu.

PMID: 28923102
PMCID: PMC5604351
DOI: 10.1186/s40425-017-0278-6

Abstract

Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, "Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most common immunocompetent and humanized models used in cancer immunology and immunotherapy research, and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop presentations and subsequent panel discussion.

Keywords: Cancer immunotherapy; Humanized mouse; Immunocompetent; Mouse models; Mouse-in-mouse; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

LMC receives reagent support from Plexxikon, Inc. AHS has patent-pending royalties from Roche and Novartis, and is an inventor on patent numbers US 8552154 B2, US 8652465 B2, and US 9102727 B2, held by Emory University (Atlanta), Dana-Farber Cancer Institute (Boston), Brigham and Women’s Hospital (Boston), and Harvard University (Cambridge), which cover the topic of PD-1-directed immunotherapy. All authors declare that they have no other financial or non-financial competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cited by

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.
Liu H, Wu W, Sun G, Chia T, Cao L, Liu X, Guan J, Fu F, Yao Y, Wu Z, Zhou S, Wang J, Lu J, Kuang Z, Wu M, He L, Shao Z, Wu D, Chen B, Xu W, Wang Z, He K. Liu H, et al. Cell Rep Med. 2022 Jun 21;3(6):100660. doi: 10.1016/j.xcrm.2022.100660. Cell Rep Med. 2022. PMID: 35732156 Free PMC article.
Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.
Du Y, Yang Y, Zheng B, Zhang Q, Zhou S, Zhao L. Du Y, et al. Oncogene. 2025 Mar;44(7):409-426. doi: 10.1038/s41388-025-03273-8. Epub 2025 Jan 25. Oncogene. 2025. PMID: 39863748 Free PMC article. Review.
Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology.
London CA, Gardner H, Zhao S, Knapp DW, Utturkar SM, Duval DL, Chambers MR, Ostrander E, Trent JM, Kuffel G. London CA, et al. Vet Comp Oncol. 2023 Dec;21(4):565-577. doi: 10.1111/vco.12935. Epub 2023 Oct 1. Vet Comp Oncol. 2023. PMID: 37778398 Free PMC article. Review.
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma.
Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M, Kulikovsaya I, Lacey SF, Mason NJ. Panjwani MK, et al. Oncoimmunology. 2019 Oct 23;9(1):1676615. doi: 10.1080/2162402X.2019.1676615. eCollection 2020. Oncoimmunology. 2019. PMID: 32002286 Free PMC article.
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Atkins MB, et al. J Immunother Cancer. 2022 Sep;10(9):e005413. doi: 10.1136/jitc-2022-005413. J Immunother Cancer. 2022. PMID: 36175037 Free PMC article.

See all "Cited by" articles

References

1. Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12:569. doi: 10.1038/nrd4090. - DOI - PubMed
1. Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 2016;29:590–597. doi: 10.1111/pcmr.12498. - DOI - PMC - PubMed
1. Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G et al. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 Mouse Melanoma Model. Pigment Cell Melanoma Res 2017. - PMC - PubMed
1. Hong E, Usiskin IM, Bergamaschi C, Hanlon DJ, Edelson RL, Justesen S, et al. Configuration-dependent presentation of multivalent IL-15:IL-15Ralpha enhances the antigen-specific T cell response and anti-tumor immunity. J Biol Chem. 2016;291:8931–8950. doi: 10.1074/jbc.M115.695304. - DOI - PMC - PubMed
1. Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med. 2016;22:1351–1357. doi: 10.1038/nm.4202. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

Affiliations

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer

Authors

Affiliations

Abstract

Conflict of interest statement

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources